ArticleAdvanced materials (Deerfield Beach, Fla.)2026
Dexime: A Selectively Enzyme-Degradable Hydrogel for Protein Therapeutic Release.
Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hydrogels are of great interest for the delivery of protein therapeutics as they obviate the denaturing shear forces and/or organic solvents common to other delivery systems. Dextrin, a polysaccharide derived from starch, has been largely ignored in the design of hydrogels, yet is biodegradable and can be modified to allow in situ gelation after injection by click-crosslinking. Herein, dextrin is modified with either ketone or aldehyde moieties and then click-crosslinked with poly(ethylene glycol)-tetraoxyamine to form dextrin-oxime (dexime) hydrogels. The rheological and mechanical properties are tunable by changing formulation parameters such as total dextrin weight percentage (wt.%) and pH. The hydrogels are injectable through a 30G needle, selectively degradable via α-amylase, yet stable and minimally swelling in the presence of other enzymes, including hyaluronidase and chondroitinase ABC (ChASE). The presence of low amounts of α-amylase in many fluids and tissues of the body allow for the slow degradation of dexime with minimal swelling. Dexime is particularly useful for local delivery of ChASE: an enzyme that degrades the aggregate scar formed after injury in the central nervous system. Dexime is cytocompatible and releases active ChASE both in vitro and in vivo as evidenced by chondroitin sulphate proteoglycan degradation in the spinal cord.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.